Medical device company Q'Apel Medical reported on Tuesday the receipt of US Food and Drug Administration clearance for its novel walrus Balloon Guide Catheter (BGC) for the neurovascular market.
The US FDA approved walrus BGC, with its 087 ID, marks a big step forward in balloon guide catheter technology and for stroke patients worldwide, added the company .
In conjunction, the walrus BGC represents the company's second US FDA-cleared technology in the past 12 months, joining the wahoo Access Catheter with Selectflex technology.
Additionally, the company expects to launch more innovative neurovascular products with speed, reliability and performance slated in the market over next year.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial